Verona Pharma plc

General Information
Business:

(Note: Not an IPO: “Our ordinary shares trade on AIM, a market of the London Stock Exchange, under the symbol “VRP.” On April 13, 2017, the last reported sale price of our ordinary shares on AIM was £1.36 per ordinary share (equivalent to $13.49 per ADS based on an assumed exchange rate of £1.00 to $1.2398).

We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Our product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, or PDE3 and PDE4, that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 12
Founded: 2005
Contact Information
Address 3 More London Riverside, London SE1 2RE UK
Phone Number +44 203 283 4200
Web Address https://www.veronapharma.com
View Prospectus: Verona Pharma plc
Financial Information
Market Cap $129.6mil
Revenues $0 mil (last 12 months)
Net Income $-6.2 mil (last 12 months)
IPO Profile
Symbol VRNA
Exchange NASDAQ
Shares (millions): 5.8
Price range $13.50 - $13.50
Est. $ Volume $77.9 mil
Manager / Joint Managers Jefferies/ Stifel
CO-Managers Wedbush PacGrow/ SunTrust Robinson Humphrey
Expected To Trade: 4/27/2017
Status:
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change